Ma, Christopher. “Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?”. Canadian IBD Today 1, no. S05 (May 11, 2023): 2–7. Accessed November 23, 2024. https://canadianibdtoday.com/article/view/1-s05-ma.